亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

三氟乙?;?2Cas: 64577-63-5

 
 
單價 10.00 / g對比
銷量 暫無
發貨 四川成都市付款后3天內
庫存 10000g起訂1g
品牌 成都云希
CAS號 64577-63-5
純度 ≥98%
分子式 C21H28F3N3O6
過期 長期有效
更新 2021-07-05 16:42
 

成都云希化工有限公司

企業會員第6年
資料未認證
保證金未繳納
詳細說明

1.Basic information:

INCI Name: Trifluoroacetyl Tripeptide-2

Synonym: ECM-Protect, Progeline

Cas No: 64577-63-5

Formula: C21H28F3N3O6

Molecular:475.47

Solubility: slightly soluble in water

Stability: stable

Odor: no

Grade: cosmetic

Source: synthetic

Formulation: available for your reference, please contact us.

COA and MSDS: available for your reference, please contact us.

Delivery: promptly from stock

Appearance: white powder

 

2.Usage: Trifluoroacetyl Tripeptide-2 reduces progerin synthesis, MMP and elastase inhibitor, increases syndecan, contracts collagen to reduce signs of aging including sagging and wrinkles

Description: Trifluoroacetyl Tripeptide-2 is a 3 amino acids peptide biomimetic of elafin that modulates progerin, a new senescence marker, for a *plete remodelling effect and reduction of the appearance of wrinkles.

 

3.Description: Trifluoroacetyl Tripeptide-2 Reduces progerin synthesis, MMP and elastase inhibitor, increases syndecan, contracts collagen to reduce signs of aging including sagging and wrinkles

 

4. Mechanism:

1. Tripeptide-2 Reduces progerin to a young cell level to delay cell senescence.

2. Tripeptide-2 Stimulates sirtuin production and activity to extend cell lifespan.

3. Tripeptide-2 Boosts collagen production and inhibits degradation enzymes activity(collagenase,elastase,MMP-1,MMP-3,MMP-9).

舉報收藏 0評論 0
更多>本企業其它產品
云希專注勝肽乙?;?49/DELISENS 乙?;?1 乙酰基四肽-2 三肽-10瓜氨酸/核心蛋白聚糖肽 Polypeptide-23 乙酰基六肽-7抗衰多肽 Sh-Decapeptide-7 Oligopeptide-21/寡肽21
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |